Questions about the immunological safety of induced pluripotent stem cells (iPSCs) should not be viewed as a roadblock in advancing research into their use, according to a new study published in the journal Cell Stem Cell. “iPSCs offer the potential to treat many diseases as an alternative or adjuvant therapy to drugs or surgery,” says Paul Knoepfler, associate professor of cell biology and human anatomy at University of California, Davis.
